Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer

Authors:

Abstract
In phase 3 trials, inactivated VZV vaccine (ZVIN) was well tolerated and efficacious against herpes zoster (HZ) in autologous HSC transplant (auto-HSCT) recipients and patients with solid tumor malignancies receiving chemotherapy (STMc) but did not reduce HZ incidence in patients with hematologic malignancies (HM). Here, we describe ZVIN immunogenicity from these studies. Patients were randomized to ZVIN or placebo (4 doses). Immunogenicity was assessed by glycoprotein ELISA (gpELISA) and VZV IFN-γ enzyme-linked immunospot (ELISPOT) assay in patients receiving all 4 doses without developing HZ at the time of blood sampling. Estimated geometric mean fold rise ratios (ZVIN/placebo) by gpELISA and IFN-y ELISPOT ~28 days postdose 4 were 2.02 (95% CI, 1.53–2.67) and 5.41 (3.60–8.12) in auto-HSCT recipients; 1.88 (1.79–1.98) and 2.10 (1.69–2.62) in patients with STMc; and not assessed and 2.35 (1.81–3.05) in patients with HM. ZVIN immunogenicity was directionally consistent with clinical efficacy in auto-HSCT recipients and patients with STMc even though HZ protection and VZV immunity were not statistically correlated. Despite lack of clinical efficacy in patients with HM, ZVIN immunogenicity was observed in this population. Immunological results did not predict vaccine efficacy in these 3 populations.
Funding Information
  • Merck Sharp and Dohme United Kingdom

This publication has 29 references indexed in Scilit: